Avenue Therapeutics Stock Price on November 8, 2024
| ATXI Stock | USD 2.06 0.02 0.98% |
Below is the normalized historical share price chart for Avenue Therapeutics extending back to June 27, 2017. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Avenue Therapeutics stands at 2.06, as last reported on the 28th of November, with the highest price reaching 2.09 and the lowest price hitting 2.00 during the day.
If you're considering investing in Avenue Stock, it is important to understand the factors that can impact its price. Avenue Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0534, which signifies that the company had a -0.0534% return per unit of standard deviation over the last 3 months. Avenue Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Avenue Therapeutics' risk adjusted performance of (0.03), and Mean Deviation of 3.15 to double-check the risk estimate we provide.
As of now, Avenue Therapeutics' Total Stockholder Equity is increasing as compared to previous years. The Avenue Therapeutics' current Stock Based Compensation is estimated to increase to about 923.3 K, while Common Stock Total Equity is projected to decrease to 1,467. . As of now, Avenue Therapeutics' Price Book Value Ratio is increasing as compared to previous years. The Avenue Therapeutics' current Price To Book Ratio is estimated to increase to 1.13, while Price Earnings Ratio is projected to decrease to (0.17). Avenue Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 27th of June 2017 | 200 Day MA 5.0564 | 50 Day MA 2.179 | Beta (0.18) |
Avenue |
Sharpe Ratio = -0.0534
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ATXI |
Estimated Market Risk
| 4.38 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Avenue Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avenue Therapeutics by adding Avenue Therapeutics to a well-diversified portfolio.
Price Book 1.5088 | Book Value 4.635 | Enterprise Value 1.3 M | Enterprise Value Ebitda (0.42) | Shares Float 1.3 M |
Avenue Therapeutics Main Headline on 8th of November 2024
Avenue Therapeutics director Jay Kranzler sells 136 in stock by investing.com
Avenue Therapeutics director Jay Kranzler sells 136 in stock
Avenue Therapeutics Valuation on November 8, 2024
It is possible to determine the worth of Avenue Therapeutics on a given historical date. On November 8, 2024 Avenue was worth 2.36 at the beginning of the trading date compared to the closed value of 2.19. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Avenue Therapeutics stock. Still, in general, we apply an absolute valuation method to find Avenue Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Avenue Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Avenue Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.26 | 2.29 | 2.19 | 2.29 | 8,583 | |
11/08/2024 | 2.36 | 2.41 | 2.18 | 2.19 | 29,567 |
| 2.10 | 2.15 | 1.97 | 2.00 | 67,257 |
| Backtest Avenue Therapeutics | | | Avenue Therapeutics History | | | Avenue Therapeutics Valuation | Previous | Next |
Avenue Therapeutics Trading Date Momentum on November 8, 2024
| On November 11 2024 Avenue Therapeutics was traded for 2.00 at the closing time. The top price for the day was 2.15 and the lowest listed price was 1.97 . The trading volume for the day was 67.3 K. The trading history from November 11, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 8.68% . The overall trading delta against the current closing price is 13.70% . |
Avenue Therapeutics Fundamentals Correlations and Trends
By evaluating Avenue Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Avenue Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Avenue financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Avenue Therapeutics Stock history
Avenue Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Avenue is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Avenue Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Avenue Therapeutics stock prices may prove useful in developing a viable investing in Avenue Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 141.2 K | 134.2 K | |
| Net Loss | -3.4 M | -3.5 M |
Avenue Therapeutics Stock Technical Analysis
Avenue Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Avenue Therapeutics Period Price Range
Low | November 28, 2024
| High |
0.00 | 0.00 |
Avenue Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Avenue Therapeutics November 28, 2024 Market Strength
Market strength indicators help investors to evaluate how Avenue Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Avenue Therapeutics shares will generate the highest return on investment. By undertsting and applying Avenue Therapeutics stock market strength indicators, traders can identify Avenue Therapeutics entry and exit signals to maximize returns
Avenue Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Avenue Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Avenue Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Avenue to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.87) | |||
| Treynor Ratio | 1.55 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Avenue Stock analysis
When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |